7 completed. 4 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow yimitasvir: new trials by email Literature Review of yimitasvir trials Research Report on yimitasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD Yimitasvir Phosphate Capsule - Renal Impairment | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 16 | 2021-04-15 | 2022-10-27 |
| To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects Yimitasvir Phosphate - Hepatic Impairment | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 16 | 2020-10-19 | 2022-10-27 |
| A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients TG-2349, DAG181, Ribavirin - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 3 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 370 | 2019-06-13 | 2021-02-04 |
| Phase 3 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 3 | Completed | Sunshine Lake Pharma Co., Ltd. | 362 | 2018-04-17 | 2020-03-18 |
| To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers TG-2349 (400 mg) plus DAG181 (200 mg), DAG181 (200 mg) plus TG-2349 (400 mg) - Healthy Chinese Volunteers | Phase 1 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 24 | 2017-10-17 | 2018-08-01 |
| Phase 2 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 129 | 2017-07-31 | 2020-03-18 |
| The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects yimitasvir, placebo - Chronic Hepatitis c | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 32 | 2014-12-03 | 2018-03-12 |
Fibrosis (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Renal Insufficiency (1)
Sunshine Lake Pharma Co., Ltd. (5) · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (2)
China (7)
Lai Wei, Doctor (2) · Pingsheng Xu (1) · Yimin Cui, Doctor (1)